Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03942653
Title Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Big Ten Cancer Research Consortium
Indications

salivary gland carcinoma

Therapies

Goserelin + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.